ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-06-23

Last Posted Date: 2007-11-29

Lead Sponsor: Abbott

Target Recruit Count: 40

Registration Number: NCT00063102

Locations: 🇺🇸
Oncology-Hematology Group of South Florida, Miami, Florida, United States
🇺🇸
Clinical Research Network, Inc., Plantation, Florida, United States
🇺🇸
Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion, Indianapolis, Indiana, United States

and more 5 locations

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Phase 4

Terminated

Conditions: End-Stage Kidney Disease

First Posted Date: 2003-06-13

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 2200

Registration Number: NCT00062699

Locations: 🇺🇸
Gambro Healthcare - Los Angeles, Los Angeles, California, United States
🇺🇸
Paul Light, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 56 locations

Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma, Soft Tissue

First Posted Date: 2003-06-04

Last Posted Date: 2007-11-29

Lead Sponsor: Abbott

Target Recruit Count: 88

Registration Number: NCT00061659

Locations: 🇺🇸
Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States

and more 2 locations

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin
Hodgkin's Lymphoma

First Posted Date: 2003-06-04

Last Posted Date: 2007-08-15

Lead Sponsor: Abbott

Target Recruit Count: 67

Registration Number: NCT00061672

Locations: 🇺🇸
Arch Medical Services, INC., St. Louis, Missouri, United States
🇺🇸
Hematology Oncology Associates, San Antonio, Texas, United States
🇺🇸
Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States

and more 10 locations

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2003-06-04

Last Posted Date: 2007-08-14

Lead Sponsor: Abbott

Target Recruit Count: 25

Registration Number: NCT00061646

Locations: 🇺🇸
University of Wisconsin, Madison,, Wisconsin, United States
🇺🇸
The West Cancer Clinic, Memphis, Tennessee, United States
🇺🇸
Oncology-Hematology Group of South Florida, Miami, Florida, United States

and more 1 locations

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

First Posted Date: 2003-05-16

Last Posted Date: 2006-08-04

Lead Sponsor: Abbott

Target Recruit Count: 370

Registration Number: NCT00060905

Locations: 🇺🇸
Brentwood Research Inst., Shreveport, Louisiana, United States
🇺🇸
AVI Clinical Research, Torrance, California, United States
🇺🇸
Comprehensive Neuroscience of SCA, Cerritos, California, United States

and more 15 locations

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

Not Applicable

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Leuprolide acetate

First Posted Date: 2003-03-21

Last Posted Date: 2008-09-17

Lead Sponsor: Abbott

Target Recruit Count: 164

Registration Number: NCT00056654

Locations: 🇺🇸
Urology Associates of Central California, Fresno, California, United States
🇺🇸
San Diego Uro-Research, San Diego, California, United States
🇺🇸
West Side Veteran Administration Medical Center, Chicago, Illinois, United States

and more 47 locations

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

First Posted Date: 2003-03-06

Last Posted Date: 2006-08-15

Lead Sponsor: Abbott

Target Recruit Count: 300

Registration Number: NCT00055523

Locations: 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
Mayo Clinic and Mayo Foundation, Rochester, Minnesota, United States
🇺🇸
Northwest Gastroenterology, Bellevue, Washington, United States

and more 40 locations

Remission in Subjects With Crohn's Disease, 1 Year Phase

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: Double-blind (DB) adalimumab placebo
Biological: DB adalimumab 40 mg eow
Biological: DB adalimumab 40 mg ew
Biological: OL adalimumab 40 mg

First Posted Date: 2003-03-05

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 276

Registration Number: NCT00055497

Locations: 🇺🇸
Northwest Gastroenterologists, S.C., Arlington Heights, Illinois, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Wake Research Associates, Weston, Florida, United States

and more 40 locations

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism
End Stage Renal Disease

First Posted Date: 2003-02-03

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 28

Registration Number: NCT00053547

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Miami Children's Hospital, Miami, Florida, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy